Forecast horizon — calibration-scored at resolution.
By 2028, CDK4/6 inhibitors will remain standard first-line for HR+/HER2− metastatic breast cancer; resistance-overcoming agents (e.g., AKT/PI3K) will be layered on top.
TL;DR · AI-generated
Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving ribociclib plus letrozole than among those received placebo plus let rozole, with a higher rate of myelosuppression in the ribocIClib group.
Your probability this resolves TRUE
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
2 events · 1 snapshot
posterior drift
71% → 71% (0pp · 1 point)
Registry data
Apr 18, 2026
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobagyi et al. · New England Journal of Medicine · 2016
· openalex W2528767298 · s2 6bffab4c
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.2016
By 2028, antibody-drug conjugates (T-DXd class) will have largely displaced T-DM1 as second-line HER2+ metastatic therapy.
0.2096
The MONALEESA-2 trial's stated primary conclusion — Adding ribociclib to letrozole improves progression-free survival in HR+/HER2− advanced breast cancer. — replicates in independent cohorts.
0.2520
By 2028, pembrolizumab-containing regimens will be first-line for >90% of eligible metastatic non-squamous NSCLC in US practice.
0.2670
The EMILIA trial's stated primary conclusion — T-DM1 improves progression-free and overall survival vs. lapatinib+capecitabine in HER2+ advanced breast cancer. — replicates in independent cohorts.
0.2698
By 2028, neoadjuvant checkpoint inhibition will be standard-of-care for stage II–III TNBC across major oncology guidelines.
0.2958
By 2028, ARNI will remain preferred over ACEi as baseline RAS modulation in HFrEF across US and EU guidelines.